Ionis Pharmaceuticals INC

Ionis Pharmaceuticals and Roche announce positive interim results from the Phase 3 IMAgINATION study of sefaxersen for IgA nephropathy, meeting its primary endpoint.

Ionis Pharmaceuticals announced that its partner Novartis' Phase 3 Lp(a)HORIZON study for pelacarsen did not meet its primary endpoint for reducing cardiovascular events.

Ionis Pharmaceuticals announces FDA approval of ZANVASTRO (zilganersen) as the first disease-modifying treatment for Alexander disease in pediatric and adult patients.

Ionis Pharmaceuticals reported second quarter 2026 financial results, highlighting strong commercial revenue growth, progress in key drug development programs, and reaffirming its 2026 financial guidance.

Ionis Pharmaceuticals and AstraZeneca announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM patients did not meet its primary efficacy endpoint.

Ionis Pharmaceuticals received FDA approval for TRYNGOLZA to treat severe hypertriglyceridemia and reduce the risk of acute pancreatitis.

Ionis Pharmaceuticals reports a net loss for Q2 2026, with revenue impacted by significant upfront payments in the prior year, while commercial revenue shows growth driven by new product sales.

Ionis Pharmaceuticals reported a significant increase in revenue for the first quarter of 2026, driven by strong commercial product sales and milestone payments, though the company still posted a net loss.

Ionis Pharmaceuticals reports significantly increased revenue and narrowed net loss in Q3 2025, driven by new product launches and strategic collaborations.

Ionis Pharmaceuticals reported a significant surge in second-quarter revenue and a return to quarterly net income, driven by new product launches and a major collaboration deal, while advancing its robust RNA-targeted therapeutic pipeline.

Ionis Pharmaceuticals announces its Q1 2025 financial results, showcasing commercial growth driven by TRYNGOLZA and WAINUA, and advancements in its neurology, cardiology, and high patient need pipeline.

Ionis Pharmaceuticals' Q3 2024 results show a net loss, but also highlight revenue from new commercial products and advancements in their drug pipeline.

Ionis Pharmaceuticals, a leader in RNA-targeted medicines, reported significant revenue growth in 2025 driven by new product launches and a robust pipeline, despite a net loss.

Ionis Pharmaceuticals reports $705 million in revenue for 2024, marking a year of commercial expansion and pipeline progress.

Ionis Pharmaceuticals highlights advancements in RNA-targeted medicines, FDA approvals, and a strong financial position with $2.3 billion in cash reserves at the end of 2023.

C Frank Bennett, EVP, Chief Scientific Officer of Ionis Pharmaceuticals Inc, reported a transaction in 110 shares of common stock on August 31, 2026.

Patrick R. O'Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals Inc, reported a transaction in 63 shares of common stock on August 31, 2026.

Brett P Monia, Chief Executive Officer and a Director of Ionis Pharmaceuticals Inc, reported a transaction in 98 shares of common stock on August 31, 2026.

Brian Birchler, EVP, Corp and Development Ops of Ionis Pharmaceuticals Inc, reported a transaction in 58 shares of common stock on August 31, 2026.

Michael R Hayden, a Director of Ionis Pharmaceuticals Inc, purchased 20,000 shares of common stock on July 30, 2026.

Peter N Reikes, a Director of Ionis Pharmaceuticals Inc, received 3,399 shares of common stock on July 15, 2026.

Ionis Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, with key proposals including director elections and equity plan amendments.

Ionis Pharmaceuticals has filed a definitive proxy statement related to its upcoming shareholder meeting.

Ionis Pharmaceuticals is asking stockholders to approve an amendment to its 2011 Equity Incentive Plan to increase the number of shares available for issuance by 4,000,000 at the 2025 annual meeting.

Ionis Pharmaceuticals has filed a definitive proxy statement related to its upcoming shareholder meeting.

Ionis Pharmaceuticals invites stockholders to its virtual 2024 Annual Meeting on June 6, 2024, featuring director elections, executive compensation advisory vote, and equity incentive plan amendment approval.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6,159,027 shares, representing 3.7% of the outstanding common stock of Ionis Pharmaceuticals Inc.

Vanguard Capital Management has reported beneficial ownership of over 8.3 million shares, representing 5.05% of Ionis Pharmaceuticals' common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Ionis Pharmaceuticals Inc. following an internal realignment.

Capital World Investors has reported an 11.1% beneficial ownership stake in Ionis Pharmaceuticals, Inc., holding 17,961,299 shares of common stock.

T. Rowe Price Investment Management, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing an 8.3% beneficial ownership stake in Ionis Pharmaceuticals Inc. common stock as of September 30, 2025.

Wellington Management Group LLP and its affiliates have reduced their beneficial ownership in Ionis Pharmaceuticals, Inc. to 4.3% of common stock, as disclosed in an amended Schedule 13G filing.